Acute polyradiculoneuropathy and Dengue Fever infection

Journée scientifique de l'IPNC 21 Novembre 2013



Dr Olivier SIMON Neurologue CHT Gaston Bourret Nouméa Nouvelle Calédonie



Plan

1-Introduction

Neurological complications of Dengue virus infection

The Guillain-Barré Syndrome (GBS)

GBS and Dengue virus infection

2- Case reports : Concomitant GBS and dengue virus infection

3- Discussion

4- Conclusion

5- Acknowledgements

1-Introduction

Neurological complications of dengue virus infection

Francisco Javier Carod-Artal, Ole Wichmann, Jeremy Farrar, Joaquim Gascón

Lancet Neurol 2013; 12: 906-19

• Proportion of Dengue virus infection with neurological manifestations :

- 0.5% to 5.4% in four studies from southeast Asia
- **21** % of cases in a prospective study from Brazil.

Neurological complications of Dengue fever can be categorised into:

- Encephalopathy
- Encephalitis
- Immune-mediated syndromes
- Dengue muscle dysfunction
- Neuro-ophthalmic disorders

Peripheral nervous system manifestations:

5% of neurological manifestations of Dengue fever

1-Introduction

Guillain-Barré Syndrome

Nobuhiro Yuki, M.D., Ph.D., and Hans-Peter Hartung, M.D.

The NEW ENGLAND JOURNAL of MEDICINE

• **GBS is characterized by** acute areflexic paralysis with albuminocytologic dissociation (present in only 50% of patients during the first week of illness)

• **Preceded by** infectious symptoms 3 days to 6 weeks in 2/3 of cases with a peak incidence between 1 and 2 weeks

• Evolution in 3 phases : progress (1-3 weeks) plateau (weeks or months) and recovery (weeks or months)

- Autoimmune origin of this syndrome is well established.
- 2 subtypes of GBS:
 - Acute inflammatory demyelinating polyneuropathy
 - Acute motor axonal neuropathy

1-Introduction



Figure 1 Relation between infections, antiganglioside antibodies, and clinical course of GBS

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome The Lancet Neurology Volume 7, Issue 10 2008 939 - 950

1- Introduction : Review of literature

- More than 20 cases of GBS following dengue virus infection were reviewed.
- Neurological symptoms occured at least one week after Dengue fever onset.

• Two cases of concomitant SGB and Dengue fever

But in one case RT-PCR in both blood and CSF samples were negative. In the other case RT-PCR was not performed Both were treated by intravenous immunoglobulins and one recovered in one week

• One case of concomitant Miller Fisher Syndrome (GBS variant) and dengue virus infection

Latency between neurolgical manifestations and dengue fever symptoms : 2 days Viral RNA in blood and CSF samples : both positive

Complete recovery : one week without treatment

2- Case reports

During the last dengue epidemy

we report 3 cases of

concomitant Dengue virus infection and

acute inflammatory demyelinating polyneuropathy

2- Case reports

- Characteristics of the 3 patients :
 - Gender: 2 males, 1 woman
 - Origins: melanesian, indonesian and caucasian
 - Mean age: 60 years old (55-68)
 - Medical history : one present old history of Basedow's disease, no treatment
- Dengue fever symptoms :
 - Acute fever, headaches, muscle and joint pain
 - No dengue haemorrhagic fever
- Neurological symptomes :
 - **Tetraparesia** with gait disorder and areflexia : 100% of cases
 - Multiple cranial nerve palsies : 66 % of cases

(Ptosis, bilateral facial palsy, swallowing troubles)

Mean latency between Dengue fever and neurological symptomes : 2 days (1-3)

2- Case reports

• Paraclinical Data :

- Electroneuromyography :

Demyelinisating disorders according to	Cornblath criterias in all cases
Motor conduction velocity slowed :	33%
Distal motor Imatencies prolonged :	66%
F waves latencies prolonged :	100%
Conduction blocs :	100%

- Cerebrospinal fluid (CSF) analysis :

Normal, no pleiocytosis and protein level normal **in all cases** Intrathecal immunoglobulin synthesis analysed in the only case : negative

Biology:
RT-PCR for dengue virus positive in both blood and CSF in all cases
IgM realised 2 cases : 100 % positive
IgG realised in all cases : 100 % negative

2- Case reports

- **Diagnosis of Dengue Fever** was performed before AIDP in only 1 case
- Treatment
 - Standard care for Guillain Barre Syndrome
 - Polyvalent intravenous immunoglobulins for all cases (2g kg)

- Evolution
 - Maximum motor deficit reached in a **one or two days**
 - No other complication of dengue virus infection
 - Global recovery after 1 week for all cases

2- Case reports

For us these cases are not Guillain-Barré Syndrome

- Concomitant infection
- Viral RNA positive in CSF
- No albuminocytologic dissociation in CSF
- Maximum neurological symptoms reached in a few days
- Plateau phase lasting a few days before complete recovery

3- Discussion

- Physiopathological hypothesis
- Secondary infection, antibody-dependant enhancement ?
 - -> But serology IgG Dengue negative for all 3 patients
- Early Guillain Barré Syndrome?
 - -> But GBS generally occurs from 3 days to 6 weeks after infection
- Demyelinisation or oedematous lesion directly due to Dengue virus?
 - -> The neurotropism of Dengue virus is well established for the central nervous system

-> The neurotropism of Dengue virus for peripheral nervous system has not been studied

3- Discussion

• Utility of intravenous immunoglobulins ?

- 6 cases of Acute Inflammatory Demyelinating Polyneuropathy occuring at early stage or seroconversion of acute VIH infection

-> 50 % of them were treated with intravenous immunoglobulin therapy before starting highly active anti-retroviral therapy and **completely recovered.**

- 1 case of concomitant GBS and dengue virus infection

-> Recovery in one week after intravenous immunoglobulins

- But the Miller Fischer syndrome reported by our colleagues was extremely similar

-> Recovery was spontaneous within 1 week.

CONCLUSION

Acute inflammatory demyelinating polyneuropathy can be observed at **the first days** of dengue fever infection

The mechanism is not understood, **demyelinisation directly due to Dengue virus is not impossible**

The use of intravenous immunoglobulins seems to be **safe and efficient.**

- Colleagues who actively contributed to this work : S.BILLOT, D.GUYON and N.MOLKO (Neurology CHT)
 E.DESCLOUX (Internal Medicine CHT)
 AC.GOURINAT (IPNC)
- Members of the scientific commitee of this congress who allowed me to present this work